We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extracellular Fluid in Resistant Hypertension

This study has been terminated.
(Insufficient accrual rate)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00141596
First Posted: September 1, 2005
Last Update Posted: June 9, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
St George's, University of London
  Purpose
The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.

Condition Intervention
Hypertension Drug: Cardura XL 4 mg bd Drug: Amiloride 5 mg bd Drug: Furosemide 40 mg bd

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension

Further study details as provided by St George's, University of London:

Primary Outcome Measures:
  • Change in ECV; change in BP

Estimated Enrollment: 32
Study Start Date: July 2003
Study Completion Date: October 2006
Detailed Description:
Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a randomised fashion, for a period of four weeks each, with BP & ECV measurement at end of each period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.; placebo.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BP >140/85
  • 3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)

Exclusion Criteria:

  • Pregnancy
  • Breast Feeding
  • Unstable heart failure
  • Chronic Liver Disease
  • Creatinine >120 mcmol/L
  • Contraindication to (or intolerance of) drug used in study
  • BP > 180/110
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00141596


Locations
United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
St George's, University of London
Investigators
Principal Investigator: Timothy WR Doulton, BSc MRCP SGUL
  More Information

ClinicalTrials.gov Identifier: NCT00141596     History of Changes
Other Study ID Numbers: LREC 03.0001
First Submitted: August 31, 2005
First Posted: September 1, 2005
Last Update Posted: June 9, 2015
Last Verified: May 2007

Keywords provided by St George's, University of London:
Resistant Hypertension
Extracellular Fluid Volume

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Furosemide
Amiloride
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Acid Sensing Ion Channel Blockers
Sodium Channel Blockers
Epithelial Sodium Channel Blockers
Diuretics, Potassium Sparing